Clarkston Capital Partners LLC Sells 3,360 Shares of Pfizer Inc. (NYSE:PFE)

Clarkston Capital Partners LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 297,045 shares of the biopharmaceutical company’s stock after selling 3,360 shares during the quarter. Clarkston Capital Partners LLC’s holdings in Pfizer were worth $12,966,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Hollencrest Capital Management lifted its stake in shares of Pfizer by 1.6% in the 3rd quarter. Hollencrest Capital Management now owns 106,359 shares of the biopharmaceutical company’s stock valued at $4,687,000 after purchasing an additional 1,667 shares during the period. Pure Financial Advisors Inc. grew its holdings in shares of Pfizer by 21.4% in the 3rd quarter. Pure Financial Advisors Inc. now owns 29,601 shares of the biopharmaceutical company’s stock valued at $1,304,000 after acquiring an additional 5,216 shares in the last quarter. Cibc Bank USA grew its holdings in shares of Pfizer by 5.0% in the 3rd quarter. Cibc Bank USA now owns 60,371 shares of the biopharmaceutical company’s stock valued at $2,661,000 after acquiring an additional 2,851 shares in the last quarter. Barometer Capital Management Inc. bought a new position in shares of Pfizer in the 3rd quarter valued at about $14,993,000. Finally, Capital Investment Services of America Inc. grew its holdings in shares of Pfizer by 14.4% in the 3rd quarter. Capital Investment Services of America Inc. now owns 11,179 shares of the biopharmaceutical company’s stock valued at $493,000 after acquiring an additional 1,405 shares in the last quarter. Hedge funds and other institutional investors own 69.45% of the company’s stock.

Several equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Credit Suisse Group reiterated a “neutral” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, January 28th. JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday. Bank of America boosted their price objective on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Fourteen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $45.61.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $42.83, for a total value of $642,450.00. Following the completion of the sale, the insider now directly owns 124,994 shares of the company’s stock, valued at approximately $5,353,493.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mikael Dolsten sold 149,553 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the completion of the sale, the insider now directly owns 390,097 shares of the company’s stock, valued at $16,988,724.35. The disclosure for this sale can be found here. Insiders sold a total of 288,726 shares of company stock worth $12,534,617 in the last 90 days. 0.09% of the stock is currently owned by company insiders.

Shares of NYSE PFE traded up $0.38 during trading on Friday, hitting $41.39. 17,704,719 shares of the company traded hands, compared to its average volume of 24,368,125. Pfizer Inc. has a fifty-two week low of $34.37 and a fifty-two week high of $46.47. The firm has a market capitalization of $246.39 billion, a P/E ratio of 13.80, a P/E/G ratio of 2.43 and a beta of 0.71. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 26.54%. The firm had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.88 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be issued a $0.36 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.48%. Pfizer’s dividend payout ratio is presently 48.00%.

ILLEGAL ACTIVITY WARNING: “Clarkston Capital Partners LLC Sells 3,360 Shares of Pfizer Inc. (NYSE:PFE)” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/pfizer-inc-pfe-shares-sold-by-clarkston-capital-partners-llc.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: What type of investment options does a Roth IRA provide?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.